Overall Survival and Response to Systemic Therapy in Metastatic Extrauterine Leiomyosarcoma
Table 2
Univariate analysis of clinicopathologic features on OS from time of metastasis.
Variable
Number of events
Median OS
value
Time to metastatic disease (years, continuous)
215
190
—
Age
≤56
104
85
2.79
0.006
>56
111
105
2.38
Primary tumor size
<5 cm
34
26
2.92
0.711
5–10 cm
81
75
2.54
>10 cm
80
69
2.69
Gender
Female
135
115
2.91
0.005
Male
80
75
2.19
Primary site
A/P or RP
151
131
2.73
0.097
Extremity
45
40
2.54
Trunk
9
9
1.74
Unknown
10
10
2.51
Margins
Negative
95
82
2.58
0.801
Positive
48
43
2.9
Grade
Low/intermediate
12
11
4.17
0.165
High
176
155
2.54
Depth
Superficial
5
4
1.49
0.538
Deep
196
173
2.69
Number of metastatic sites
<3
144
125
2.83
0.002
≥3
71
65
2.03
KPS
≤70
10
9
2.35
0.115
>70
133
116
2.91
Lung metastases
No
102
90
2.46
0.586
Yes
113
100
2.71
Liver metastases
No
159
143
2.71
0.529
Yes
56
47
2.37
Treatment for recurrence
Chemo only
49
40
2.37
0.077
Local therapy only
33
30
3.06
Chemo + local treatment
40
35
2.98
Year of metastatic disease
Before 2000
51
48
2.23
0.387
2000 and after
164
142
2.71
Treatment for recurrence only analyzed in patients presenting with primary disease. value comes from score test. A/P: abdomen/pelvis, RP: retroperitoneal, and chemo: chemotherapy.
